Key Points
- CEO Martine Rothblatt sold 9,500 shares on April 8 at an average price of $580.45 for about $5.51 million, leaving her with 40,513 shares (a reported 19% reduction) under a pre-arranged Rule 10b5-1 plan.
- United Therapeutics reported quarterly EPS of $7.70, beating estimates while revenue of $790.2 million missed consensus; the stock trades near $575 with a market cap of about $25.2 billion and a 52-week range of $269.92–$607.89.
- Several analysts have raised price targets recently and the consensus rating is a Moderate Buy (nine Buys vs. three Holds) with an average target around $586.00.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm's stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $580.45, for a total value of $5,514,275.00. Following the sale, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $23,515,770.85. This represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
United Therapeutics Stock Down 1.2%
Shares of United Therapeutics stock opened at $574.77 on Friday. The company has a market capitalization of $25.19 billion, a price-to-earnings ratio of 20.60, a PEG ratio of 1.67 and a beta of 0.75. The stock's 50-day simple moving average is $514.63 and its 200-day simple moving average is $483.21. United Therapeutics Corporation has a 52 week low of $269.92 and a 52 week high of $607.89.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The company had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. During the same quarter last year, the company earned $6.19 EPS. The firm's quarterly revenue was up 7.4% on a year-over-year basis. On average, equities analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on UTHR. Wells Fargo & Company raised their target price on shares of United Therapeutics from $486.00 to $575.00 and gave the company an "equal weight" rating in a research note on Tuesday, March 31st. Royal Bank Of Canada increased their price objective on shares of United Therapeutics from $587.00 to $643.00 and gave the company an "outperform" rating in a report on Thursday, February 26th. UBS Group lifted their target price on United Therapeutics from $655.00 to $705.00 and gave the stock a "buy" rating in a report on Thursday, March 5th. Bank of America increased their price target on United Therapeutics from $569.00 to $626.00 and gave the company a "neutral" rating in a research note on Tuesday, March 31st. Finally, HC Wainwright lifted their price objective on United Therapeutics from $600.00 to $660.00 and gave the stock a "buy" rating in a research note on Tuesday, March 31st. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $586.00.
Read Our Latest Research Report on United Therapeutics
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the business. Torren Management LLC bought a new stake in shares of United Therapeutics during the 4th quarter worth approximately $26,000. Activest Wealth Management increased its stake in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock worth $29,000 after buying an additional 56 shares during the period. Entrust Financial LLC bought a new stake in United Therapeutics during the 4th quarter valued at about $31,000. Wilmington Savings Fund Society FSB lifted its holdings in United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company's stock valued at $37,000 after buying an additional 49 shares in the last quarter. Finally, Harbor Capital Advisors Inc. purchased a new stake in United Therapeutics in the 4th quarter valued at about $48,000. Hedge funds and other institutional investors own 94.08% of the company's stock.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
